Sigma receptors have been classified into sigma-1 and sigma-2 based on pharmacologic profile, function and molecular size. [1] [2] [3] They are found in high density in the central nervous system (CNS) and endocrine, immune, and other peripheral organs. [4] [5] [6] Furthermore, they are expressed in a variety of human and rodent tumor cell lines. 7, 8) Recently, cDNAs of sigma-1 were cloned, and their amino acid sequences were deduced. [9] [10] [11] [12] However, sigma-2 has not yet been cloned.
The functional and biological role of sigma receptors is still incompletely understood. In the CNS, they have been shown to be involved in the regulation of neurotransmitter release, neurotransmitter receptor function, learning and memory processes, and regulation of movement and posture. 13) Although they are present in peripheral tissues such as the liver, kidney, and endocrine organs, functions in these tissues is much less understood. In addition, sigma receptors may be associated with such as Alzheimer's disease, 14) ischemia, 15) schizophrenia, 16) depression, 17) and certain psychiatric disorders. 18) It is possible that the development of sigma receptor radioligands would allow for the study of intact human brain to assess the occupancy of neuroleptics and their metabolites at these sites via tomographic imaging.
For imaging sigma receptors using single photon-emission computed tomography (SPECT) [19] [20] [21] and positron emission tomography (PET), [22] [23] [24] several radiolabeled ligands have been developed. Recently, a new highly selective sigma-1 agonist, 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl) piperazine (SA4503), has been reported as a potential drug candidate with high binding affinity to sigma receptors, 25, 26) and its 11 C-labeled compound has been reported. [27] [28] [29] [30] [31] We have explored the feasibility of using radioiodinated sigma receptor ligands for functional sigma receptor studies in the living brain with SPECT. We have recently reported the design, synthesis, and biological evaluation of a novel series of iodinated SA4503 analogues. 32 29) In this paper, the in vivo kinetics of the radioligands in the brain did not necessarily parallel the in vitro affinity for sigma receptors. The discrepancy between affinities of the radioligands and their time-activity curves might depend on other factors. Moreover, 11 C-and 18 F-labeled SA4503 derivatives showed similar lipophilicity. Thus it appears that the difference between o-BON and m-BON might be due to various factors.
In contrast to high brain uptake and retention, the blood accumulation was low, resulting in good brain-blood ratios (o-BON: 5.42, 6.25, 7.93, m-BON: 6.85, 7.25, 9.22, at 1, 2, and 5 h after injection, respectively). In the peripheral organs, high uptake was observed in the liver, kidney, lung, and pancreas. These accumulations of [ 125 I] o-and m-BON in the brain and brain-blood ratios showed the desired retention and contrast for SPECT imaging.
The TLC analysis of radioactivity in the brain showed that more than 90% of the original radioactivity was observed at the position of the intact compound (data not shown). For each labeled compound, more than 90% was maintained in the brain as an intact compound 5 h after injection, and the radioactivity of metabolites including free iodine was less than 10% each. Furthermore, the increase in [ I] o-and m-BON in all cerebral tissues examined was distributed uniformity, after which differences were observed in the regional cerebral distribution. At 1 h after injection, the highest concentration of radioactivity of [ 125 I] o-and m-BON was detected in the cortex (2.78% and 3.35% dose/g, respectively) and cerebellum (2.93% and 3.35% dose/g, respectively), followed by moderate uptake in the striatum (2.27% and 2.62% dose/g, respectively) and hippocampus (2.18% and 2.24% dose/g, respectively). These accumulations were comparable with published sigma receptor distribution. 28, [33] [34] [35] [36] Further studies on the selective binding of [ High uptake occurred in the peripheral organs, followed by reduced radioactivity uptake in these organs after pretreatment with haloperidol (Fig. 3) . The [ to the control. Generally, the liver and kidney show higher nonspecific binding than other organs. Binding is not completely inhibited by pretreatment with haloperidol fully, and thus sigma receptors are still present in these organs. Thus, in these organs, the effects of nonspecific binding are readily apparent. These data imply that [ cortex, vestibular nucleus, inferior colliculus, and pons nucleus, and moderate uptake in the thalamus, hippocampus, hypothalamus, and parietal cortex. This regional brain distribution is consistent with published histochemical sigma receptor distribution 28, [33] [34] [35] [36] and [ 11 C] SA4503 brain distribution. [27] [28] [29] [30] [31] The binding of [ ] m-BON were prepared by the method previously described (specific activity, approximately 74 TBq/mmol).
32) The HPLC system used includes a Waters M-600 pump, Lambada-Max 481 ultraviolet detector, Beckman 170 NaI radioactivity detector, and Cosmosil 5 C 18 -AR-II column (10ϫ250 mm, Nacalai Tesque). Radioactivity was measured using an Aloka ARC-300 NaI(Tl) gamma scintillation counter. Wistar rats and male ddY mice were obtained from Japan SLC Co., Ltd. These animals were kept at least 1 week before the experiments. Animal chow and drinking water were allowed ad libitum. Animals were housed and experiments were performed according to guidelines stipulated by the Osaka University of Pharmaceutical Sciences Animal Care and Use Committee. 
